Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
Year: 2022
Type: article
Abstract: Enhanced de novo lipogenesis mediated by sterol regulatory element-binding proteins (SREBPs) is thought to be involved in nonalcoholic steatohepatitis (NASH) pathogenesis. In this study, we assessed the impact of SREBP inhibition on NASH and liver cancer development in murine models. Unexpectedly, SREBP inhibition via deletion of the SREBP cleavage-activating protein (SCAP) in the liver exacerbated liver injury, fibrosis, and carcinogenesis despite markedly reduced hepatic steatosis. These phenotypes were ameliorated by restoring SREBP function. Transcriptome and lipidome analyses revealed that SCAP/SREBP pathway inhibition altered the fatty acid (FA) composition of phosphatidylcholines due to both impaired FA synthesis and disorganized FA incorporation into phosphatidylcholine via lysophosphatidylcholine acyltransferase 3 (LPCAT3) downregulation, which led to endoplasmic reticulum (ER) stress and hepatocyte injury. Supplementation with phosphatidylcholines significantly improved liver injury and ER stress induced by SCAP deletion. The activity of the SCAP/SREBP/LPCAT3 axis was found to be inversely associated with liver fibrosis severity in human NASH. SREBP inhibition also cooperated with impaired autophagy to trigger liver injury. Thus, excessively strong and broad lipogenesis inhibition was counterproductive for NASH therapy; this will have important clinical implications in NASH treatment.
DOI: 10.1172/jci151895
Authors: Satoshi Kawamura, Yuki Matsushita, Shigeyuki Kurosaki, Mizuki Tange, Naoto Fujiwara, Yuki Hayata, Yoku Hayakawa, Nobumi Suzuki, Masahiro Hata, Mayo Tsuboi, Takahiro Kishikawa, Hiroto Kinoshita, Takuma Nakatsuka, Masaya Sato, Yotaro Kudo, Yujin Hoshida, Atsushi Umemura, Akiko Eguchi, Tsuneo Ikenoue, Yoshihiro Hirata, Motonari Uesugi, Ryosuke Tateishi, Keisuke Tateishi, Mitsuhiro Fujishiro, Kazuhiko Koike, Hayato Nakagawa
Institutions: The University of Tokyo, The University of Texas Southwestern Medical Center, The Institute of Medical Science, Asahi Life Foundation, Kyoto Prefectural University of Medicine, Mie University, Institute of Medical Science, The University of Tokyo, Kyoto University, Institute for Integrated Cell-Material Sciences, Kyoto University
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,200
Funders: Bristol-Myers Squibb, Naito Foundation, Takeda Science Foundation, Cell Science Research Foundation, Uehara Memorial Foundation, Japan Agency for Medical Research and Development, European Commission, Mitsubishi Foundation, NOVARTIS Foundation (Japan) for the Promotion of Science, Life Science Foundation of Japan, National Institutes of Health, Japan Society for the Promotion of Science, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G1008859853, G1148361885, G1153329094, G152670155, Molecular Prognostic Indicators in Liver Cirrhosis and Cancer, NASHから肝硬変・肝癌へと至る過程における脂肪沈着減少(burned-out NASH)の意義解明とそれに基づく新規治療戦略, G3485959468, G4010235196, Investigation of the molecular mechanisms and cellular origins of combined hepatocellular-cholangiocarcinoma using hepatocellular carcinoma-specific gene recombination system in mice, G468806068, G498955371, ウイルス性肝疾患を含む代謝関連肝がん発生の病態解明に関する研究, Unraveling the Pathophysiology of NASH through Changes in LipoQuality, G6471879342, Reverse-engineering precision liver cancer chemoprevention, G7791563723, The mechanism of carcinogenesis of GAPPS
OpenAlex ID: W4226154198
